Topic: precision medicine
Several cancer drug candidates are designed to kill tumor cells by attacking certain targets, but they work in other ways, researchers found.
Celsius is using a new set of tools it thinks will unlock some of the secrets of autoimmune diseases and cancer—notably those that do not have a specific genomic mutation, which make up about 70% of all cancers.
Chinook Therapeutics raised $65 million to do for kidney disease what precision medicine has done for cancer. It aims to be in the clinic by 2021.
Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.
Renovacor is working on a gene therapy for small group of patients with dilated cardiomyopathy that could spare them from a heart transplant.
Pfizer has tapped Syapse to help provide precision medicine data gathering and real-world outcomes research for its work in cancer.
GNS Healthcare raised $23 million from the VC arms of drugmakers and health insurers to build out its AI-driven precision medicine platform.
Syapse’s collaboration with its one-time benefactor Amgen aims to mine real-world evidence for insights into cancer drug development.
Scientists suggest that using more precise CRISPR techniques could contain blood stem cells' p53-mediated response to gene editing.
Versant Ventures is unveiling Black Diamond Therapeutics, a biotech developing cancer treatments for an “undrugged and unexplored” group of oncogenes.